{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:13Z","timestamp":1781646733882,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["16206"],"award-info":[{"award-number":["16206"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To determine genome-wide transcriptional coverage of well-characterized genes, gene candidates, and splice variants associated with invasive process on bladder carcinogenesis (BC), we investigated the whole-genome gene expression profile of high-grade Turkish BC patients. We collected high-grade bladder tumours (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912) and paired standard tissue samples (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912). To find differentially expressed genes related to bladder cancer\u2019s metastatic pattern, we performed the human whole-genome expression profiling through the Illumina Human HT-12 Expression Beadchip system. Ingenuity Pathway Systems (IPA), i-Pathway Guide and Cytoscape software were used to determine statistically significant genes, networks, biological pathways between tumour and control groups. Cyclin A2 (CCNA2), CDC20, CDC45, MMP1, MMP3, MMP9, MMP10, STAT1, STAT2, TNFRSF1A, TNFSF10, and TUBB3 were significantly upregulated in bladder cancer cases. We showed that biological reactions, including the degradation of collagen and extracellular matrix and matrix metalloproteinases activation reactions, were found the most statistically significant pathways in BC. We also determined that inflammation and cytokine signalling could be related to the progression of bladder carcinogenesis. The genes differentially expressed could be molecular indicators for early prediction of bladder carcinogenesis.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-36530-1","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:04:02Z","timestamp":1774555442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genome-wide transcriptional profiling identifies molecular markers associated with early carcinogenesis in high-grade bladder cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Rifat Burak","family":"Ergul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Kucukgergin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Birsu","family":"Cincin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bedia","family":"Cakmakoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcuk","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzevat","family":"Tefik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Oner","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismet","family":"Nane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruk","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Seckin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"36530_CR1","unstructured":"IARC. Estimated Number of New Cases in 2022, Worldwide, Both Sexes, All Ages. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"36530_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","volume":"76","author":"R Nadal","year":"2019","unstructured":"Nadal, R. & Bellmunt, J. Management of metastatic bladder cancer. Cancer Treat. Rev. 76, 10\u201321. https:\/\/doi.org\/10.1016\/j.ctrv.2019.04.002 (2019).","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"36530_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41585-019-0208-0","volume":"16","author":"C Alifrangis","year":"2019","unstructured":"Alifrangis, C., McGovern, U., Freeman, A., Powles, T. & Linch, M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat. Rev. Urol. 16(8), 465\u2013483. https:\/\/doi.org\/10.1038\/s41585-019-0208-0 (2019).","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"36530_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","volume":"143","author":"CC Guo","year":"2019","unstructured":"Guo, C. C. & Czerniak, B. Bladder cancer in the genomic era. Arch. Pathol. Lab. Med. 143(6), 695\u2013704. https:\/\/doi.org\/10.5858\/arpa.2018-0329-RA (2019).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"36530_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig, T. W. et al. NCCN Guidelines(R) insights: Bladder cancer, version 3.2024. J. Natl. Compr. Cancer Netw. 22(4), 216\u2013225. https:\/\/doi.org\/10.6004\/jnccn.2024.0024 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"21","key":"36530_CR6","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389(21), 1961\u20131971. https:\/\/doi.org\/10.1056\/NEJMoa2308849 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"36530_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00428-019-02618-5","volume":"475","author":"MDC Rodriguez Pena","year":"2019","unstructured":"Rodriguez Pena, M. D. C. et al. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Arch. 475(3), 349\u2013356. https:\/\/doi.org\/10.1007\/s00428-019-02618-5 (2019).","journal-title":"Virchows Arch."},{"issue":"5","key":"36530_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for molecular pathology. Genet. Med. 17(5), 405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30 (2015).","journal-title":"Genet. Med."},{"issue":"12","key":"36530_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2018.13152","volume":"320","author":"J Mersch","year":"2018","unstructured":"Mersch, J. et al. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA 320(12), 1266\u20131274. https:\/\/doi.org\/10.1001\/jama.2018.13152 (2018).","journal-title":"JAMA"},{"issue":"7463","key":"36530_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415\u2013421. https:\/\/doi.org\/10.1038\/nature12477 (2013).","journal-title":"Nature"},{"issue":"10","key":"36530_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","volume":"16","author":"AK Schneider","year":"2019","unstructured":"Schneider, A. K., Chevalier, M. F. & Derre, L. The multifaceted immune regulation of bladder cancer. Nat. Rev. Urol. 16(10), 613\u2013630. https:\/\/doi.org\/10.1038\/s41585-019-0226-y (2019).","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"36530_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11684-018-0656-6","volume":"12","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. & Weinberg, R. A. Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities. Front. Med. 12(4), 361\u2013373. https:\/\/doi.org\/10.1007\/s11684-018-0656-6 (2018).","journal-title":"Front. Med."},{"key":"36530_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","volume":"45","author":"F Massari","year":"2016","unstructured":"Massari, F. et al. Metabolic phenotype of bladder cancer. Cancer Treat. Rev. 45, 46\u201357. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.005 (2016).","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"36530_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15(1), 25\u201341. https:\/\/doi.org\/10.1038\/nrc3817 (2015).","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"36530_CR15","first-page":"8324","volume":"10","author":"JS Ruan","year":"2017","unstructured":"Ruan, J. S. et al. CCNA2 facilitates epithelial-to-mesenchymal transition via the integrin alphavbeta3 signaling in NSCLC. Int. J. Clin. Exp. Pathol. 10(8), 8324\u20138333 (2017).","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"36530_CR16","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1038\/s41467-018-07552-9","volume":"9","author":"Q Bayard","year":"2018","unstructured":"Bayard, Q. et al. Cyclin A2\/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nat. Commun. 9(1), 5235. https:\/\/doi.org\/10.1038\/s41467-018-07552-9 (2018).","journal-title":"Nat. Commun."},{"issue":"4","key":"36530_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3892\/ol_00000121","volume":"1","author":"CK Chuang","year":"2010","unstructured":"Chuang, C. K., Pang, S. T., Chuang, T. J. & Liao, S. K. Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma. Oncol. Lett. 1(4), 691\u2013695. https:\/\/doi.org\/10.3892\/ol_00000121 (2010).","journal-title":"Oncol. Lett."},{"issue":"8","key":"36530_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/iju.12431","volume":"21","author":"E Wieczorek","year":"2014","unstructured":"Wieczorek, E., Wasowicz, W., Gromadzinska, J. & Reszka, E. Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: A mini-review. Int. J. Urol. 21(8), 744\u2013752. https:\/\/doi.org\/10.1111\/iju.12431 (2014).","journal-title":"Int. J. Urol."},{"issue":"24","key":"36530_CR19","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1158\/1078-0432.CCR-13-3336","volume":"20","author":"X Du","year":"2014","unstructured":"Du, X. et al. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer. Clin. Cancer Res. 20(24), 6324\u20136335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3336 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"36530_CR20","doi-asserted-by":"publisher","first-page":"9855","DOI":"10.1007\/s13277-016-4872-x","volume":"37","author":"S Candido","year":"2016","unstructured":"Candido, S. et al. Diagnostic value of neutrophil gelatinase-associated lipocalin\/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumour Biol. 37(7), 9855\u20139863. https:\/\/doi.org\/10.1007\/s13277-016-4872-x (2016).","journal-title":"Tumour Biol."},{"key":"36530_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/1471-2407-14-310","volume":"14","author":"G Zhang","year":"2014","unstructured":"Zhang, G., Miyake, M., Lawton, A., Goodison, S. & Rosser, C. J. Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer 14, 310. https:\/\/doi.org\/10.1186\/1471-2407-14-310 (2014).","journal-title":"BMC Cancer"},{"issue":"6","key":"36530_CR22","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/j.1582-4934.2011.01302.x","volume":"15","author":"J Decock","year":"2011","unstructured":"Decock, J., Thirkettle, S., Wagstaff, L. & Edwards, D. R. Matrix metalloproteinases: Protective roles in cancer. J. Cell. Mol. Med. 15(6), 1254\u20131265. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01302.x (2011).","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"36530_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/156800913804486610","volume":"13","author":"Y Sun","year":"2013","unstructured":"Sun, Y. et al. Inhibition of STAT signalling in bladder cancer by diindolylmethane: Relevance to cell adhesion, migration and proliferation. Curr. Cancer Drug Targets 13(1), 57\u201368 (2013).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"8","key":"36530_CR24","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/sj.onc.1209149","volume":"25","author":"M Itoh","year":"2006","unstructured":"Itoh, M. et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25(8), 1195\u20131204. https:\/\/doi.org\/10.1038\/sj.onc.1209149 (2006).","journal-title":"Oncogene"},{"issue":"3","key":"36530_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bjc.2015.233","volume":"113","author":"SJ Thomas","year":"2015","unstructured":"Thomas, S. J., Snowden, J. A., Zeidler, M. P. & Danson, S. J. The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 113(3), 365\u2013371. https:\/\/doi.org\/10.1038\/bjc.2015.233 (2015).","journal-title":"Br. J. Cancer"},{"issue":"47","key":"36530_CR26","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","volume":"22","author":"GA Orr","year":"2003","unstructured":"Orr, G. A., Verdier-Pinard, P., McDaid, H. & Horwitz, S. B. Mechanisms of taxol resistance related to microtubules. Oncogene 22(47), 7280\u20137295. https:\/\/doi.org\/10.1038\/sj.onc.1206934 (2003).","journal-title":"Oncogene"},{"key":"36530_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.humpath.2016.11.005","volume":"61","author":"A Hinsch","year":"2017","unstructured":"Hinsch, A. et al. betaIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Hum. Pathol. 61, 210\u2013220. https:\/\/doi.org\/10.1016\/j.humpath.2016.11.005 (2017).","journal-title":"Hum. Pathol."},{"key":"36530_CR28","doi-asserted-by":"publisher","first-page":"10975","DOI":"10.1038\/ncomms10975","volume":"7","author":"JB Hein","year":"2016","unstructured":"Hein, J. B. & Nilsson, J. Interphase APC\/C-Cdc20 inhibition by cyclin A2-Cdk2 ensures efficient mitotic entry. Nat. Commun. 7, 10975. https:\/\/doi.org\/10.1038\/ncomms10975 (2016).","journal-title":"Nat. Commun."},{"issue":"3","key":"36530_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00277-016-2860-2","volume":"96","author":"K Ben Younes","year":"2017","unstructured":"Ben Younes, K., Doghri, R., Mrad, K., Ben Romdhane, N. & Ben Aissa-Fennira, F. Cyclin A2 as a potential differential marker of splenic diffuse red pulp small B-cell lymphoma: A report of the first case. Ann. Hematol. 96 (3), 511\u2013512. https:\/\/doi.org\/10.1007\/s00277-016-2860-2 (2017).","journal-title":"Ann. Hematol."},{"issue":"3","key":"36530_CR30","doi-asserted-by":"publisher","first-page":"101042831769223","DOI":"10.1177\/1010428317692233","volume":"39","author":"R Shi","year":"2017","unstructured":"Shi, R. et al. Cell division cycle 20 overexpression predicts poor prognosis for patients with lung adenocarcinoma. Tumour Biol. 39(3), 1010428317692233. https:\/\/doi.org\/10.1177\/1010428317692233 (2017).","journal-title":"Tumour Biol."},{"issue":"7","key":"36530_CR31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1080\/15384101.2016.1152424","volume":"15","author":"C Kohler","year":"2016","unstructured":"Kohler, C. et al. Cdc45 is limiting for replication initiation in humans. Cell. Cycle 15(7), 974\u2013985. https:\/\/doi.org\/10.1080\/15384101.2016.1152424 (2016).","journal-title":"Cell. Cycle"},{"issue":"1","key":"36530_CR32","first-page":"1","volume":"11","author":"B Ham","year":"2016","unstructured":"Ham, B., Fernandez, M. C., D\u2019Costa, Z. & Brodt, P. The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res. 11(1), 1\u201327 (2016).","journal-title":"Trends Cancer Res."},{"issue":"3","key":"36530_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.yexcr.2007.10.005","volume":"314","author":"MA Rivas","year":"2008","unstructured":"Rivas, M. A. et al. TNF alpha acting on TNFR1 promotes breast cancer growth via p42\/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp. Cell Res. 314(3), 509\u2013529. https:\/\/doi.org\/10.1016\/j.yexcr.2007.10.005 (2008).","journal-title":"Exp. Cell Res."},{"issue":"1","key":"36530_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1947601909358324","volume":"1","author":"Z Wu","year":"2010","unstructured":"Wu, Z. et al. Autophagy Blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. Genes Cancer 1(1), 40\u201349. https:\/\/doi.org\/10.1177\/1947601909358324 (2010).","journal-title":"Genes Cancer"},{"key":"36530_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1476-4598-13-70","volume":"13","author":"K Singh","year":"2014","unstructured":"Singh, K. et al. Autophagic flux determines cell death and survival in response to Apo2L\/TRAIL (dulanermin). Mol. Cancer 13, 70. https:\/\/doi.org\/10.1186\/1476-4598-13-70 (2014).","journal-title":"Mol. Cancer"},{"issue":"12","key":"36530_CR36","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.4161\/auto.22145","volume":"8","author":"W He","year":"2012","unstructured":"He, W. et al. Attenuation of TNFSF10\/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1\/RIP1-mediated MAPK8\/JNK activation. Autophagy 8(12), 1811\u20131821. https:\/\/doi.org\/10.4161\/auto.22145 (2012).","journal-title":"Autophagy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36530-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:16Z","timestamp":1781643436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36530-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36530"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36530-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was approved by the Istanbul Faculty of Medicine Ethical Committee (Number: 1037-337).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"15150"}}